Philips aims to advance cardiac MRI technology through AI-driven research
Philips and Mayo Clinic announced a research collaboration to advance cardiac MRI technology through AI integration. The partnership aims to reduce complex MRI exam times and improve workflow efficiency by combining proprietary AI technologies from both organizations. The research will evaluate lower-field-strength MRI solutions to expand access for patients with metallic implants and explore ways to make cardiac MRI more accessible. With ischemic heart disease being the leading cause of global mortality and costing $252.2 billion in the U.S. (2021), this initiative targets improved patient care and broader MRI accessibility.
Philips e Mayo Clinic hanno annunciato una collaborazione di ricerca per avanzare la tecnologia della risonanza magnetica cardiaca attraverso l'integrazione dell'IA. L'obiettivo della partnership è ridurre i tempi complessi degli esami di risonanza magnetica e migliorare l'efficienza del flusso di lavoro combinando le tecnologie di intelligenza artificiale proprietarie di entrambe le organizzazioni. La ricerca valuterà soluzioni MRI a bassa intensità di campo per ampliare l'accesso ai pazienti con impianti metallici e esplorerà modi per rendere la risonanza magnetica cardiaca più accessibile. Con la malattia coronarica ischemica che è la principale causa di mortalità globale e costa 252,2 miliardi di dollari negli Stati Uniti (2021), questa iniziativa punta a migliorare l'assistenza ai pazienti e ad aumentare l'accessibilità della risonanza magnetica.
Philips y Mayo Clinic anunciaron una colaboración de investigación para avanzar en la tecnología de MRI cardíaca mediante la integración de IA. La asociación tiene como objetivo reducir los tiempos complejos de los exámenes de MRI y mejorar la eficiencia del flujo de trabajo mediante la combinación de tecnologías de IA patentadas de ambas organizaciones. La investigación evaluará soluciones de MRI de baja intensidad de campo para ampliar el acceso a pacientes con implantes metálicos y explorará formas de hacer la MRI cardíaca más accesible. Con la enfermedad cardíaca isquémica siendo la principal causa de mortalidad mundial y costando 252.2 mil millones de dólares en EE. UU. (2021), esta iniciativa tiene como objetivo mejorar la atención al paciente y una mayor accesibilidad a la MRI.
Philips와 Mayo Clinic이 인공지능 통합을 통해 심장 MRI 기술을 발전시키기 위한 연구 협력을 발표했습니다. 이 파트너십은 두 조직의 독점 AI 기술을 결합하여 복잡한 MRI 검사 시간을 줄이고 작업 흐름 효율성을 개선하는 것을 목표로 합니다. 연구는 금속 이식물을 가진 환자를 위한 접근성을 확장하기 위해 저장 강도 MRI 솔루션을 평가하고, 심장 MRI를 보다 쉽게 접근하도록 만드는 방법을 탐구할 것입니다. 허혈성 심장병은 전 세계 사망 원인 1위이며, 미국에서 2522억 달러(2021)의 비용이 드는 만큼, 이 이니셔티브는 환자 치료 개선과 MRI 접근성을 넓히는 것을 목표로 하고 있습니다.
Philips et Mayo Clinic ont annoncé une collaboration de recherche pour faire avancer la technologie de l'IRM cardiaque grâce à l'intégration de l'IA. Le partenariat vise à réduire les temps d'examen IRM complexes et à améliorer l'efficacité des flux de travail en combinant les technologies IA propriétaires des deux organisations. La recherche évaluera les solutions IRM à faible intensité de champ pour élargir l'accès aux patients avec des implants métalliques et explorera des moyens de rendre l'IRM cardiaque plus accessible. Étant donné que la maladie cardiaque ischémique est la principale cause de mortalité dans le monde et coûte 252,2 milliards de dollars aux États-Unis (2021), cette initiative vise à améliorer les soins aux patients et à élargir l'accès à l'IRM.
Philips und Mayo Clinic haben eine Forschungspartnerschaft angekündigt, um die Technologie der kardiologischen MRT durch die Integration von KI voranzubringen. Die Partnerschaft zielt darauf ab, die komplexen MRT-Untersuchungszeiten zu verkürzen und die Effizienz des Arbeitsablaufs zu verbessern, indem die proprietären KI-Technologien beider Organisationen kombiniert werden. Die Forschung wird niedrigfeldstarke MRT-Lösungen evaluieren, um den Zugang für Patienten mit metallischen Implantaten zu erweitern und Wege zu erkunden, um die kardiologische MRT zugänglicher zu machen. Da ischämische Herzkrankheit die häufigste Todesursache weltweit ist und in den USA Kosten von 252,2 Milliarden Dollar (2021) verursacht, zielt diese Initiative auf eine verbesserte Patientenversorgung und eine breitere Zugänglichkeit der MRT ab.
- Partnership with prestigious Mayo Clinic enhances research capabilities
- Potential to reduce MRI scan times and improve operational efficiency
- Technology could expand market reach by enabling less experienced staff to perform complex cardiac MRI
- Leadership in sustainable MRI with BlueSeal technology saved 2.75M liters of helium across 1,500+ installations
- Opportunity to tap into market for patients with metallic implants (3.9% of U.S. population)
- None.
Insights
This research collaboration between Philips and Mayo Clinic represents a significant advancement in cardiac MRI technology. The integration of AI aims to solve three critical industry challenges: lengthy exam times, accessibility and staff shortages.
The market opportunity is substantial, with ischemic heart disease costing
Philips' BlueSeal magnet technology demonstrates proven commercial success with over 1,500 installations, validating their expertise in this space. While the collaboration's outcomes aren't guaranteed, the combination of Mayo Clinic's clinical expertise and Philips' technical capabilities positions this initiative favorably for market success.
The AI implementation strategy here is comprehensive, targeting multiple phases of the MRI workflow. Key technological differentiators include:
- AI-assisted scan optimization for faster acquisition times
- Workflow improvements for less experienced operators
- Lower-field-strength solutions for implant compatibility
Philips' helium-free operation technology has already demonstrated significant environmental and cost benefits, saving 2.75 million liters of helium. This established track record in MRI innovation suggests strong execution capability for this new AI initiative. The collaboration with Mayo Clinic adds valuable clinical validation potential, which is important for healthcare AI adoption.
December 3, 2024
Collaboration intends to leverage proprietary AI technology from Philips and Mayo Clinic to target breakthroughs in ease-of-use and efficiency to bring high-quality diagnostic MRI and better care to more patients with heart disease
Amsterdam, the Netherlands and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA) and Mayo Clinic today announced a research collaboration aimed at advancing MRI for cardiac applications. Through this investigation, Philips and Mayo Clinic will look to harness the power of AI and the expertise of Mayo Clinic physicians to increase operational efficiency by shortening complex MRI exams and improving workflow for radiologists.
Ischemic heart disease is the world’s leading cause of mortality, accounting for
“From the patient perspective, MRI scans can be stressful. A complex cardiac MRI exam can take over an hour, which is often challenging for patients who suffer from claustrophobia inside the bore of the scanner, find it difficult to lie still or are unable to hold their breath for the required time,” said Ioannis Panagiotelis, Ph.D., Business Leader of MRI at Philips. “By applying AI at every stage of a cardiac MRI exam, we intend to expand access and greatly improve the patient experience, increase departmental efficiency, and deliver the detailed diagnostic information needed for optimal patient outcomes.”
Applying AI to transform the patient experience and accelerate MRI exam times
The investigation intends to leverage Mayo Clinic’s proprietary AI technology in combination with Philips' AI-driven technology. Combining these investigational technologies can potentially help reduce MRI scan times, and improve the efficiency needed to relieve the burden on healthcare professionals and mitigate today's chronic shortage of trained staff. With the benefit of AI, even less experienced radiographers may be able to successfully perform complex cardiac MRI exams.
Expanding MRI cardiac access to wider patient populations
The research will also evaluate the potential of lower-field-strength MRI solutions developed by Philips. These solutions are designed to enable MRI installations in a broader range of locations and provide safer scanning options for individuals with implants sensitive to high magnetic fields. Around
Proven leader in diagnostic MRI helium-free operations
With its unique, innovative BlueSeal magnet technology, Philips is a recognized leader in sustainable, affordable cardiovascular MRI. It was the first company to introduce helium-free operations in MRI scanners in 2018, with nearly 2.75 million liters of helium saved, across more than 1,500 installations worldwide to date [5]. Join Philips at RSNA 2024 to learn more.
[1] World Health Organization (WHO) Fact Sheet: The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
[2] Centers for Disease Control and Prevention (CDC) Fact Sheet: Heart Disease Facts. https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html
[3] https://www.philips.co.uk/healthcare/education-resources/publications/fieldstrength/mri-and-mr-conditional-implants.
[4] Kalin R, Stanton MS. Current clinical issues for MRI scanning of pacemaker and defibrillator patients. Pacing Clin Electrophysiol. 2005;28(4):326-328. doi: 10.1111/j.1540-8159.2005.50024.x https://pubmed.ncbi.nlm.nih.gov/15826268/
[5] https://www.usa.philips.com/healthcare/resources/landing/the-next-mr-wave/sealed-mr-technology?nocache
For further information, contact:
Kathy O’Reilly
Philips Global External Relations
Tel.: +1 978 221 8919
Email: kathy.oreilly@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- Patient preparing for a cardiac scan on the Philips Ingenia Ambition X MR system
- Philips Ingenia Ambition X MR system
FAQ
What is the goal of Philips (PHG) and Mayo Clinic's MRI research collaboration?
How many helium-free MRI installations has Philips (PHG) achieved worldwide?